ACAD vs TECH · P/E 15, rev $957.8M vs P/E 65, rev $1.22B
ACADIA Pharmaceuticals Inc (ACAD) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported ACAD revenue for 2024-12-31 was $957.8M. Net income was $226.5M. Revenue was up 314.6% from 2023-12-31 to 2024-12-31. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the ACAD and TECH stock pages for the full models.
Not investment advice.